Navigation Links
Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
Date:10/22/2008

PALO ALTO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its 2008 third quarter conference call and webcast will be held on Wednesday, November 5, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the third quarter ended September 30, 2008.

The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-398-9367 or 612-332-7517. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 966597. The archive will be available from approximately 6:00 p.m. Eastern time on November 5 through November 19, 2008.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
8. Telik Announces First Quarter 2008 Financial Results
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Rockville, MD (PRWEB) September 17, 2014 ... Small Business Innovation Research (SBIR) grant to support the ... award will provide ITI with approximately $255,000 over one ... a leading cause of food allergy, affect over one ... anaphylaxis behind peanut allergy. Tree nut exposure is also ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... LAUDERDALE, Fla. , Sept. 17, 2014 Alternative ... an agreement to form a Special Purpose Vehicle in partnership ... based Jatropha centric agro energy company. The SPV shall be ... registered entity with AFAI as majority shareholder. The SPV shall ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... DIEGO, March 16 Prometheus Laboratories Inc., a specialty ... received New York State approval for PROMETHEUS(R) IBS Diagnostic, ... syndrome (IBS). This novel test incorporates 10 biomarkers, ... algorithm to help physicians diagnose patients with IBS."One out ...
... N.J., March 16 DOR BioPharma, Inc. (OTC Bulletin ... it has appointed Gregg Lapointe, CPA, MBA, to its ... Executive Officer of Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau), a company ... patients with rare diseases. Sigma-Tau is DOR,s North American ...
... experts will address the benefits of rigorous early phase ... American Society for Clinical Pharmacology and Therapeutics (ASCPT), to ... Harbor, Maryland from March 18 - 21, 2009. The ... be to help biopharmaceutical companies understand best practice approaches ...
Cached Biology Technology:Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 2DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 3DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors 4PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4
(Date:9/17/2014)... Transmission of bacterial infections, including MRSA and MSSA ... microscopic bumps that mimic the scaly surface of ... open access journal Antimicrobial Resistance and Infection ... different materials prevented the spread of human disease ... named Sharklet, is an arrangement of ridges formulated ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... A new report demonstrates how a sensitive imaging ... bacteria in chronic infections. Listeria monocytogenes is ... illness and death. Listeria outbreaks recently claimed twenty ... most common cause of bacterial meningitis in newborns, and ...
... for simple taskswould have smiled at one of leptin,s mechanisms ... fat-derived hormone enlists the sympathetic nervous system to prevent bone-making ... discharge insulin. The study will appear online December 22, ... print issue of The Journal of Cell Biology ...
... the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News.,Please credit the ... the source for this information. ALL CONTENT ... is embargoed for 9 a. m., Eastern Time, ...
Cached Biology News:New research lights up chronic bacterial infection inside bone 2Leptin's long-distance call to the pancreas 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 2American Chemical Society's Weekly PressPac -- Dec. 17, 2008 3American Chemical Society's Weekly PressPac -- Dec. 17, 2008 4American Chemical Society's Weekly PressPac -- Dec. 17, 2008 5American Chemical Society's Weekly PressPac -- Dec. 17, 2008 6American Chemical Society's Weekly PressPac -- Dec. 17, 2008 7American Chemical Society's Weekly PressPac -- Dec. 17, 2008 8
... precision pressure regulator and pressurized syringe holder for ... Steady flow rate Microinjecting Fine ... Can be added to any new or existing ... manufacturer, even homemade. Connect to house air or ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: